Skip Navigation
Skip to contents

Clin Endosc : Clinical Endoscopy

OPEN ACCESS

Articles

Page Path
HOME > Clin Endosc > Volume 59(2); 2026 > Article
Systematic Review and Meta-analysis Outcomes associated with bilateral plastic versus metal stents for palliation in malignant hilar biliary obstruction: an updated meta-analysis from the United States
Raveena S. Boodram1orcid, Shyam Vedantam2orcid, Sunil Amin2orcid, Sean Bhalla2orcid, Jodie A. Barkin2orcid, Mahmoud Mahfouz2orcid, Shria Kumar2orcid
Clinical Endoscopy 2026;59(2):223-233.
DOI: https://doi.org/10.5946/ce.2025.149
Published online: March 9, 2026

1Department of Medicine, Jackson Memorial Hospital, University of Miami, Miami, FL, USA

2Division of Digestive Health and Liver Diseases, Department of Medicine, University of Miami, Miami, FL, USA

Correspondence: Raveena S. Boodram Department of Medicine, Jackson Memorial Hospital, University of Miami, 1611 NW 12th Ave, Miami, FL 33136, USA E-mail: raveena.boodram@gmail.com
Current affiliation: Gastroenterology, Hepatology & Motility Division, University of Kansas Medical Center, Kansas City, KS, USA
• Received: July 8, 2025   • Revised: August 17, 2025   • Accepted: August 25, 2025

© 2026 Korean Society of Gastrointestinal Endoscopy

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 2,321 Views
  • 76 Download
prev next
  • Background/Aims
    Endoscopic methods are favorable for palliation of malignant hilar biliary obstruction (MHBO) given its minimally invasive nature. This meta-analysis aimed to evaluate outcomes related to bilateral plastic stents (PS) versus bilateral metal stents (MS) in MHBO palliation.
  • Methods
    Databases were searched through November 2023. Only studies that directly compared bilateral PS and bilateral MS in MHBO were included. The primary outcome was clinical success. Secondary outcomes included technical success, adverse events, postprocedural cholangitis, recurrent biliary obstruction, endoscopic reintervention, and conversion to percutaneous drainage. Mantel-Haenszel pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using a random-effects model. Statistical heterogeneity was assessed using the I2 statistic and publication bias was assessed using funnel plots.
  • Results
    One randomized controlled trial and three retrospective cohort studies involving 420 patients were included. Bilateral MS had non-significant superior clinical success, lower rates of reintervention, and lower rates of adverse events, including postprocedural cholangitis. There was no difference in technical success or need for external drainage. Bilateral PS had increased odds of recurrent biliary obstruction (pooled OR, 1.79; 95% CI, 1.15-2.81; p=0.01).
  • Conclusions
    The selection of bilateral PS or MS for MHBO palliation should remain an individualized decision.
Malignant hilar biliary obstruction (MHBO) can be caused by cholangiocarcinoma or metastatic disease to the liver or peri-hilar lymph nodes and is associated with a poor prognosis as it is often detected at an advanced stage.1,2 Biliary decompression is offered in these cases to ameliorate symptoms of cholestasis (such as jaundice and pruritus) or to optimize the patient for oncologic or surgical therapies.3,4 Multiple factors should be considered when selecting the biliary drainage method, including location of biliary obstruction, resectability, involvement of the cystic duct, degree of intrahepatic dilation, presence of liver metastases and ascites, presence of duodenal obstruction, previous surgical history, and risk of bleeding.1 Methods of decompression include surgical resection, endoscopic retrograde cholangiopancreatography (ERCP), percutaneous transhepatic biliary drainage (PTBD), and endoscopic ultrasound-guided biliary drainage.5
MHBO can cause jaundice, palliation of which improves quality of life by alleviating pruritis, lethargy, and anorexia.6 Previous studies have suggested a goal of at least 25% of the liver drainage volume be redirected for adequate drainage.7,8 However, new guidelines recommend greater than 50% drainage of total liver volume to improve survival.9,10 Frequently, to achieve drainage of more than 50% of the liver volume, bilateral stent placement in high-grade MHBO is required. One effective drainage option is PTBD. PTBD can be superior to endoscopic drainage in certain instances, with previous studies showing improved rates of technical and clinical success in advanced hilar cholangiocarcinoma.11,12 However, PTBD can be inconvenient and uncomfortable for the patient, and is frequently complicated by external tube dislodgement, need for repeat drain exchange, infection, and possible seeding metastasis.6,13 Therefore, endoscopic palliation, specifically bilateral stenting, may be preferred.
Endoscopic palliation is an optimal management strategy for inoperable disease given its minimally invasive nature and short recovery times. However, it remains a technically difficult procedure and there is no universal consensus on endoscopic technique for biliary decompression, especially considering technical feasibility, cost-effectiveness, and short and long term outcomes.14 When ERCP is undertaken, controversies exist in the literature whether plastic stents (PS) or metal stents (MS) should be used and if these stents should be placed unilaterally or bilaterally.15,16 Previous studies have suggested that MS have lower rates of occlusion, therapeutic failure, need for reintervention, and cholangitis.17 While some studies have demonstrated higher rates of technical success with unilateral versus bilateral stenting, with comparable rates of functional success and early and late complications, other studies have found that bilateral drainage is associated with fewer reinterventions and longer stent patency in malignant hilar disease.18,19 The aim of this study was to compare outcomes between bilateral PS and bilateral MS in MHBO palliation.
Literature search
PubMed, Google Scholar, and Embase were searched from inception through November 30, 2023, to identify studies that utilized bilateral PS and bilateral MS for MHBO decompression. Review was completed by the investigators (R.S.B. and S.V.) utilizing the search terms “malignant hilar obstruction,” “bilateral stent,” “biliary tract neoplasm,” “biliary malignancy,” “biliary obstruction,” “cholestasis,” “self-expanding metal stent,” and “plastic stent.” Backward citation searching was done to identify potential articles missed during initial search. Titles and abstracts were screened for eligibility (R.S.B. and S.V.).
Selection criteria & data extraction
Eligible studies were randomized controlled trials, cross-sectional studies, or cohort studies that utilized endoscopically placed bilateral PS or MS as part of a palliative decompression strategy in patients with MHBO. Articles published from any year or in any language were included. Abstracts were excluded as they could not be assessed for publication bias.
For each study, data on publication year, country of origin, study size, study design, study population, inclusion and exclusion criteria, endoscopic technique, number of patients in each group, PS and MS, and age were collected. The primary outcome was clinical success. Secondary outcomes included technical success, adverse events, post-procedure cholangitis, recurrent biliary obstruction, need for endoscopic reintervention, and conversion to percutaneous drainage.
After an initial review of the collected articles, studies utilizing bilateral PS and bilateral MS were largely unmatched in quantity, favoring bilateral MS placement. Thus, to mitigate heterogeneity between groups, only individual studies offering direct comparisons between bilateral PS and bilateral MS in the treatment of MHBO were included in this meta-analysis.
Publication bias and quality assessment
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist for transparency in reporting was followed.20 To assess quality of the cohort studies, the Newcastle-Ottawa Scale for quality assessment was used.21 Funnel plots were produced to evaluate for publication bias.
Definitions
Technical success was defined uniformly by two of the included articles as successful bilateral stent placement.22,23 Among the four articles, the broadest shared definition of clinical success was a decrease in the total serum bilirubin level by 50% within four weeks.22-25 Adverse events were characterized as acute cholangitis, acute cholecystitis, or liver abscess22; post-ERCP pancreatitis or cholecystitis23; cholangitis, bleeding requiring endoscopic hemostasis or blood transfusion, pancreatitis, or perforation24; and cholangitis, jaundice, or bleeding.25 Although Okuno et al.23 did not provide a definition of acute cholangitis, the remaining three studies generally agreed that acute cholangitis presented as fever or a systemic inflammatory response in the setting of jaundice, cholestasis, and/or right upper quadrant pain.22,24,25 Finally, recurrent biliary obstruction was not specifically defined by Paik et al.22 or Kim et al.24 It was defined in the two remaining studies as elevated serum bilirubin and/or liver enzymes with either imaging evidence of biliary dilation or concerns about cholangitis.23,25
Statistical analysis
Statistical analysis was performed using RevMan 5.4 software (Cochrane Collaboration). Mantel-Haenszel pooled odds ratios (ORs) and 95% confidence intervals (CIs) for the outcomes were constructed using a random-effects model. p<0.05 was considered statistically significant. Statistical heterogeneity was assessed using the I2. Publication bias was assessed using funnel plots.
The PRISMA flowchart of search results and included studies is shown in Figure 1. Studies were excluded for several reasons such as using only a single MS or PS, comparing unilateral stenting with bilateral stenting, and identifying duplicate cases. Finally, four studies were included: one randomized controlled trial22 and three retrospective cohort studies23-25 involving a total of 420 patients (226 patients underwent bilateral PS placement and 194 patients underwent bilateral MS placement). Baseline characteristics and quality assessments of the included studies are shown in Table 1.22-25
Kim et al.24 reported that 100% of the included cases presented with MHBO due to cholangiocarcinoma, while the etiology of MHBO was heterogeneous in the other three studies,22,23,25 as further characterized in Table 2.22-25 The studies did not uniformly report whether one stent was placed per hepatic lobe or if both stents were placed to drain a single lobe. Stent characteristics and placement techniques are listed in Table 3.22-25 One study was single center24 while three studies were multicenter.22,23,25 Based on the Newcastle-Ottawa Scale, the quality of all the studies was good. A summary of the pooled ORs is shown in Table 4.22-25 Overall heterogeneity was moderate as the I2 value for the primary outcome was 73%, but ranged as low as 0% for other outcomes. There was no evidence of publication bias for the primary outcome seen by funnel plot (Supplementary Fig. 1).
All four studies reported clinical success. The clinical success rates in the PS and MS groups were 169/226 (74.8%) and 179/194 (92.2%), respectively. This difference was not statistically significant (pooled OR, 0.32; 95% CI, 0.07–1.55; p=0.16; Fig. 2, Table 5).
All four studies reported technical success. The technical success rates in the PS and MS groups were 226/226 (100%) and 193/194 (99.5%), respectively. This was not statistically significant (pooled OR, 3.08; 95% CI, 0.12–78.02; p=0.50; Fig. 2, Table 5).
Three studies reported adverse events.22,23,25 The adverse event rates in the PS and MS groups were 30/159 (18.9%) and 18/159 (11.3%), respectively. This was not statistically significant (pooled OR, 1.32; 95% CI, 0.25–7.09; p=0.75; Fig. 2, Table 5). Adverse events included post-ERCP pancreatitis, cholecystitis, cholangitis, liver abscess, bleeding, and perforation.
Three studies reported postprocedural cholangitis.22,23,25 The rates of postprocedural cholangitis in the PS and MS groups were 51/159 (32.1%) and 31/160 (19.5%), respectively. This was not statistically significant (pooled OR, 1.96; 95% CI, 0.77–4.97; p=0.16; Fig. 2, Table 5).
Three studies reported the incidence of recurrent biliary obstruction.22,23,25 The rates of recurrent biliary obstruction in the PS and MS groups were 87/159 (54.7%) and 64/159 (40.3%), respectively. This was statistically significant (pooled OR, 1.79; 95% CI, 1.15–2.81; p=0.01; Fig. 2, Table 5).
Three studies reported the need for endoscopic reintervention.22,24,25 The rate of reintervention in the PS and MS groups was 154/201 (76.6%) and 62/169 (36.7%), group. This was not statistically significant (pooled OR, 6.56; 95% CI, 0.52–82.08; p=0.14; Fig. 2, Table 5).
While three studies reported on time to recurrent biliary obstruction, only one of the three reported a mean time to recurrent obstruction of 96 days for PS versus 190 days for MS.22 Okuno et al.23 reported a median time to recurrent obstruction of 226 days for PS (range, 5–563 days) versus 169 days for MS (range, 10–665 days) and Kim et al.24 reported median time of 56 days for PS (range, 7–201 days) versus 112 days for MS (range, 77.5–143.5 days). Owing to discrepancies in the reported metrics, this endpoint could not be addressed in the statistical analysis.
Three studies reported the need for external or percutaneous drainage.22-24 The rate of percutaneous drain placement in the PS and MS groups were 20/130 (15.4%) and 12/98 (12.2%), respectively. This was not statistically significant (pooled OR, 1.01; 95% CI, 0.37–2.73; p=0.98; Fig. 2, Table 5).
In this meta-analysis, we compared the outcomes of bilateral PS and bilateral MS strategies for MHBO. Bilateral MS had non-significant superior clinical success, lower rates of reintervention, and lower rates of adverse events, including postprocedural cholangitis. The two groups were equivalent in terms of technical success and need for external drainage. Based on these parameters, it can be argued that no single technique is superior. Nevertheless, there were increased odds of recurrent biliary obstruction with bilateral PS compared to bilateral MS, which was a statistically significant finding.
The most common cause of MHBO is cholangiocarcinoma.26 Unfortunately, treatment is often palliative and may include a combination of chemotherapy, radiation therapy, and/or endoscopic intervention. In one observational study of the natural history of unresectable intrahepatic and hilar cholangiocarcinoma, overall survival time was 3.9±7.8 months (median±SD) in the absence of surgical resection, chemotherapy, and radiation therapy.27 For hilar cholangiocarcinoma in particular, Park et al.27 found that patients with serum albumin >3.0 g/dL had longer survival, while individuals with a baseline serum bilirubin >10.0 mg/dL and serum carcinoembryonic antigen level >30 ng/mL had shorter survival. In this observational study, there was no correlation between survival and Bismuth-Corlette classification, perhaps because this classification system only characterizes the local hepatobiliary distribution of the tumor, which may be unrelated to tumor staging.
ERCP in MHBO can be technically challenging, and its complexity can be graded according to several variables. For example, there are several types of MHBO. The Asia-Pacific Consensus recommends PTBD for advanced MHBO (Bismuth types III and IV) rather than endoscopic palliation, which can be advised for lower-grade MHBO (Bismuth types I and II).10 This may be due to degree of difficulty of ERCP. While there is no standardized system for grading ERCP complexity, several have been reported in the literature.28-30 Schutz and Abott suggest that endoscopic metal stenting for high-grade MHBO is the most difficult level ERCP.28 The more challenging the ERCP, the lower the likelihood of achieving technical and clinical success, with an increased likelihood of adverse outcomes, a characterization that applies to bilateral stent placement. The studies included in this meta-analysis reported the Bismuth classification of their included patients by bilateral PS versus bilateral MS, although they were not individually stratified by outcome. This is an important variable to report in future studies when considering palliation methods.
Given the purpose of the present study, specifically regarding MHBO palliation, this implies the preclusion of surgical resection even for those who have achieved remission or cure from metastatic disease. Importantly, these patients are committed to indefinite management with ERCP, which poses a taxing undertaking for the provider and lengthy procedure time for the patient. Therefore, technical success, clinical success, and average procedure time for endoscopic reintervention, all stratified according to whether the index endoscopic intervention used bilateral MS or PS, would be key components of future analyses to aid clinical decision-making.
Previous recommendations have suggested that if the predicted survival of the patient was greater than three months, then MS should be placed.10 Although more expensive compared to PS, MS are thought to have a longer patency duration, are less likely to become occluded, and allow for additional drainage of side branch ducts.31-33 In three of the four studies, uncovered MS were used, though there was no uniform description of whether the MS were placed stent-in-stent or stent-by-stent.23-25 Our study found that while there was an increased odds of recurrent biliary obstruction with bilateral PS compared to bilateral MS (a finding compatible with current literature on the propensity for PS occlusion), this did not lead to a statistically significant difference in postprocedural cholangitis, endoscopic reintervention, or conversion to PTBD between bilateral PS and bilateral MS. It may be that patients were outliving the life of PS and then converting to PTBD without attempting endoscopic reintervention (though this was not seen in this study); this may have been limited by the follow-up periods in the individual studies.
Post-ERCP cholangitis is a potential adverse event associated with therapeutic procedures. Recent studies have shown that the rate of post-ERCP cholangitis ranges from 2.4% to 19.5%.34-37 Post-ERCP cholangitis is the leading cause of sepsis and mortality after ERCP. Previous studies have identified risk factors for post-ERCP cholangitis to include cancer diagnosis, placement of multiple biliary stents at index ERCP, low serum albumin level, and especially hilar obstruction.34,35,37 This is in line with previous data showing that hilar stricture location was a significant predictor of early PS occlusion.38 This is thought to be secondary to elevated biliary pressure due to cholangiocarcinoma, difficult biliary cannulation with prolonged procedure times, and subsequent mucosal damage allowing translocation of bacterial endotoxins to penetrate the weakened blood-biliary barrier.36 Although our study did not find a statistical difference between bilateral PS and bilateral MS for pooled rate of post-procedure cholangitis, the cumulative rates appear to be slightly higher than previously reported. This may be due to the baseline patient population comprising those who had MHBO and underwent complex bilateral stenting procedures.
This study had several limitations. As mentioned above, the studies included in the meta-analysis did not report outcomes based on the Bismuth classification of the included patients, type of MS used, or method of bilateral MS placement; therefore, these factors could not be analyzed. There was heterogeneity in the placement of the stents across or above the papilla. Furthermore, while the patients in the Xia et al.25 study were undergoing their index ERCP (and the majority of the patients in the Kim et al.24 study), the Okuno et al.23 and Paik et al.22 studies do not explicitly comment on this factor; having to obtain biliary access to a native papilla and placing bilateral stents would increase the case complexity. As such, we were unable to perform subgroup analysis on these important factors. Furthermore, there was no uniformity in the type of PS used; PS varied in size (diameter), length, and type (straight versus pigtail) among the studies. Each of these may have been a confounding factor. Additionally, two studies used propensity score matching, which may have falsely increased the pooled technical success rates for both MS and PS.23,25 For example, of the 420 included cases of bilateral MS and PS, there was only one case of failure. Given the high technical and clinical success rates reported in the studies, it may be questioned whether the same rates would be replicated at other centers and in the community, and whether there may have been a selection or recall bias introduced into the selected studies. Finally, the total number of cases was small, possibly because of the complexity of this procedure. Therefore, further studies investigating these techniques are recommended to characterize the outcomes of bilateral PS and bilateral MS in MHBO.
In conclusion, this meta-analysis reported similar outcomes for bilateral PS and bilateral MS for MHBO. There were similar rates of clinical and technical success, adverse events, postprocedural cholangitis, endoscopic reintervention, and conversion to PTBD, while there were increased odds of recurrent biliary obstruction with bilateral PS compared to bilateral MS. These new findings can provide evidence for choosing a bilateral MS approach in patients with longer life expectancy, as assessed by the clinician (e.g., based on the burden of malignant disease, patient functional status, anticipated adjunctive therapies including chemotherapy or radiation therapy, and perioperative risk). Naitoh and Inoue39 described an algorithmic approach to palliative biliary decompression in MHBO, considering the expected prognosis, Bismuth classification of malignancy, and expected drainage volume of the liver. Cost effectiveness in the selection of bilateral MS versus bilateral PS is a key consideration for future studies. Importantly, the decision to place bilateral PS or MS should be tailored to the experience and expertise of the endoscopist. Ultimately, both options are viable for palliation of jaundice in MHBO, and individualized decision-making on a case-by-case basis may be the best option for stent selection with the presently available data.
Supplementary Fig. 1. Funnel plots demonstrating no obvious publication bias.
ce-2025-149-Supplementary-Fig-1.pdf
Supplementary materials related to this article can be found online at https://doi.org/10.5946/ce.2025.149.
Fig. 1.
Literature review flowchart. Describes literature search methodology and exclusion criteria. MS, metal stent; PS, plastic stent.
ce-2025-149f1.jpg
Fig. 2.
Forest plots for (A) clinical success, (B) technical success, (C) adverse events, (D) post-procedural cholangitis, (E) recurrent biliary obstructiona), (F) endoscopic reintervention, and (G) percutaneous drainage. M-H, Mantel-Haenszel; CI, confidence interval; MS, metal stent; PS, plastic stent. a)Denotes statistical significance.
ce-2025-149f2.jpg
ce-2025-149f3.jpg
Table 1.
Baseline characteristics of the included studies
Study Year Country Study size (n) Design PS (n) MS (n) Male (%) Age (yr, median or mean±SD) Follow-up endpoint Follow-up (day)
PS MS PS MS PS MS PS MS
Okuno et al.23 2023 Japan 76 Retrospective cohort 38 38 60 53 Median Median Death Death 871 1,116
Paik et al.22 2024 Korea 50 Randomized controlled trial 25 25 60 56 70.4±9.7 71.6±9.8 Recurrent biliary obstruction Recurrent biliary obstruction 270 270
Kim et al.24 2021 Korea 102 Retrospective cohort 67 35 60 69 Median Median Cholangitis, death Cholangitis, death 365 365
Xia et al.25 2021 China 262 Retrospective cohort 96 96 60 54 64±12.2 65.8±13.0 Death Death 900 900

SD, standard deviation; PS, plastic stent; MS, metal stent.

Table 2.
Etiologies of MHBO by study
Study Etiology of MHBO
Okuno et al.23 Biliary tract cancer (54/76)
Metastatic cancer, other site (17/76)
Hepatocellular carcinoma (5/76)
Paik et al.22 Cholangiocarcinoma (42/50)
Gallbladder cancer (6/50)
Metastatic cancer, other site (2/50)
Kim et al.24 Cholangiocarcinoma (102/102)
Xia et al.25 Cholangiocarcinoma (171/262)
Gallbladder cancer (47/262)
Hepatocellular carcinoma (27/262)
Metastatic cancer, other site (17/262)

MHBO, malignant hilar biliary obstruction.

Table 3.
Stent type and description
Study PS MS
Okuno et al.23 7 Fr, variable length Niti-S large cell D-type biliary stent, Bonastent M-hilar, HILZO stent, BileRush, Zilver 635 stent, Zeo stent, and JOSTENT SelfX stent, Hanarostent. All self-expanding MS were 8 mm or 10 mm in diameter. Placed either partially stent-in-stent or side by side.
Paik et al.22 7 Fr straight (Cotton-Leung Biliary Stent) or double pigtail (Zimmon Biliary stent), variable length 10–15 cm Fully covered COMVI II stent. All self-expanding MS were 6 mm in diameter. Placed side by side.
Kim et al.24 NR Uncovered self-expandable MS.
Xia et al.25 7–10 F (Boston Scientific Matrik; Cook Medical) 12–18 cm in length Uncovered self-expandable MS. Boston Scientific or MicroTech. 6–8 mm in diameter and 8–12 cm in length.

PS, plastic stent; MS, metal stent; NR, not reported.

Table 4.
Data stratified by study and outcome
Study Study size (n) Design Technical success (n) Clinical success (n) Adverse event (n) Post-procedure cholangitis (n) Recurrence (n) Endoscopic reintervention (n) External (percutaneous) drainage (n)
PS MS PS MS PS MS PS MS PS MS PS MS PS MS
Okuno et al.23,a) 76 Retrospective cohort 38 37 37 37 2 6 20 19 20 19 20 19 0 3
Paik et al.22 50 Randomized controlled trial 25 25 19 22 8 8 6 5 16 10 NR NR 1 1
Kim et al.24 102 Retrospective cohort 67 35 44 25 NR NR NR NR NR NR 38 14 19 8
Xia et al.25 192 Retrospective cohort 96 96 69 95 20 4 25 7 51 35 96 29 NR NR

PS, plastic stent; MS, metal stent; NR, not reported.

a)Propensity score matching explains the discrepancy between n=76 with 38 PS and 37 MS.

Table 5.
Comparison of pooled event rates
PS event (n) MS event (n) OR (95% CI) p-value
Clinical success 169/226 179/194 0.32 (0.07–1.55) 0.16
Technical success 226/226 193/194 3.08 (0.12–78.02) 0.50
Adverse events 30/159 18/159 1.32 (0.25–7.09) 0.75
Post-procedure cholangitis 51/159 31/160 1.96 (0.77–4.97) 0.16
Recurrent obstruction 87/159 64/159 1.79 (1.15–2.81) 0.01a)
Endoscopic reintervention 154/201 62/169 6.56 (0.52–82.08) 0.14
Percutaneous drainage 20/130 12/98 1.01 (0.37–2.73) 0.98

PS, plastic stent; MS, metal stent; OR, odds ratio; CI, confidence interval.

a)Statistically significant difference. The p-value of difference percentages is also reported.

  • 1. Paik WH, Park DH. Endoscopic management of malignant biliary obstruction. Gastrointest Endosc Clin N Am 2024;34:127–140.ArticlePubMed
  • 2. Puli SR, Kalva N, Pamulaparthy SR, et al. Bilateral and unilateral stenting for malignant hilar obstruction: a systematic review and meta-analysis. Indian J Gastroenterol 2013;32:355–362.ArticlePubMedPDF
  • 3. Dumonceau JM, Tringali A, Papanikolaou IS, et al. Endoscopic biliary stenting: indications, choice of stents, and results: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline: updated October 2017. Endoscopy 2018;50:910–930.ArticlePubMed
  • 4. Vozzo CF, Sanaka MR. Endoscopic management of pancreaticobiliary disease. Surg Clin North Am 2020;100:1151–1168.ArticlePubMed
  • 5. Vedantam S, Amin S. Endoscopic ultrasound-guided biliary interventions in liver disease. Clin Liver Dis 2022;26:101–114.ArticlePubMed
  • 6. Lee TH, Moon JH, Park SH. Biliary stenting for hilar malignant biliary obstruction. Dig Endosc 2020;32:275–286.ArticlePubMedPDF
  • 7. Dowsett JF, Vaira D, Hatfield AR, et al. Endoscopic biliary therapy using the combined percutaneous and endoscopic technique. Gastroenterology 1989;96:1180–1186.ArticlePubMed
  • 8. Polydorou AA, Chisholm EM, Romanos AA, et al. A comparison of right versus left hepatic duct endoprosthesis insertion in malignant hilar biliary obstruction. Endoscopy 1989;21:266–271.ArticlePubMed
  • 9. Vienne A, Hobeika E, Gouya H, et al. Prediction of drainage effectiveness during endoscopic stenting of malignant hilar strictures: the role of liver volume assessment. Gastrointest Endosc 2010;72:728–735.ArticlePubMed
  • 10. Rerknimitr R, Angsuwatcharakon P, Ratanachu-ek T, et al. Asia-Pacific consensus recommendations for endoscopic and interventional management of hilar cholangiocarcinoma. J Gastroenterol Hepatol 2013;28:593–607.ArticlePubMed
  • 11. Paik WH, Park YS, Hwang JH, et al. Palliative treatment with self-expandable metallic stents in patients with advanced type III or IV hilar cholangiocarcinoma: a percutaneous versus endoscopic approach. Gastrointest Endosc 2009;69:55–62.ArticlePubMed
  • 12. Jang SI, Hwang JH, Lee KH, et al. Percutaneous biliary approach as a successful rescue procedure after failed endoscopic therapy for drainage in advanced hilar tumors. J Gastroenterol Hepatol 2017;32:932–938.ArticlePubMedPDF
  • 13. Wang L, Lin N, Xin F, et al. A systematic review of the comparison of the incidence of seeding metastasis between endoscopic biliary drainage and percutaneous transhepatic biliary drainage for resectable malignant biliary obstruction. World J Surg Oncol 2019;17:116.ArticlePubMedPMCPDF
  • 14. Lee TH, Lee SJ, Moon JH, et al. Technical tips and issues of biliary stenting, focusing on malignant hilar obstruction. Minerva Gastroenterol Dietol 2014;60:135–149.ArticlePubMed
  • 15. Yasuda I, Mukai T, Moriwaki H. Unilateral versus bilateral endoscopic biliary stenting for malignant hilar biliary strictures. Dig Endosc 2013;25 Suppl 2:81–85.ArticlePubMed
  • 16. Hong W, Sun X, Zhu Q. Endoscopic stenting for malignant hilar biliary obstruction: should it be metal or plastic and unilateral or bilateral? Eur J Gastroenterol Hepatol 2013;25:1105–1112.ArticlePubMed
  • 17. Sawas T, Al Halabi S, Parsi MA, et al. Self-expandable metal stents versus plastic stents for malignant biliary obstruction: a meta-analysis. Gastrointest Endosc 2015;82:256–267.ArticlePubMed
  • 18. Aghaie Meybodi M, Shakoor D, Nanavati J, et al. Unilateral versus bilateral endoscopic stenting in patients with unresectable malignant hilar obstruction: a systematic review and meta-analysis. Endosc Int Open 2020;8:E281–E290.ArticlePubMedPMC
  • 19. Lee TH, Kim TH, Moon JH, et al. Bilateral versus unilateral placement of metal stents for inoperable high-grade malignant hilar biliary strictures: a multicenter, prospective, randomized study (with video). Gastrointest Endosc 2017;86:817–827.ArticlePubMed
  • 20. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.ArticlePubMedPMC
  • 21. Wells G, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [Internet]. Ottawa Hospital Research Institute; 2019 [cited 2020 Nov 15]. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
  • 22. Paik WH, Jung MK, Kim DU, et al. Side-by-side placement of fully covered metal stents versus conventional 7F plastic stents in malignant hilar biliary obstruction: Prospective randomized controlled trial. Dig Endosc 2024;36:473–480.ArticlePubMed
  • 23. Okuno M, Iwata K, Iwashita T, et al. Utility of bilateral intraductal plastic stent for malignant hilar biliary obstruction compared with bilateral self-expandable metal stent: a propensity score-matched cohort analysis. Gastrointest Endosc 2023;98:776–786.ArticlePubMed
  • 24. Kim JY, Lee SG, Kang D, et al. The comparison of endoscopic biliary drainage in malignant hilar obstruction by cholangiocarcinoma: bilateral metal stents versus multiple plastic stents. Gut Liver 2021;15:922–929.ArticlePubMedPMC
  • 25. Xia MX, Pan YL, Cai XB, et al. Comparison of endoscopic bilateral metal stent drainage with plastic stents in the palliation of unresectable hilar biliary malignant strictures: large multicenter study. Dig Endosc 2021;33:179–189.ArticlePubMedPDF
  • 26. Covey AM, Getrajdman GI. Hilar biliary obstruction: malignant masquerades. Semin Intervent Radiol 2007;24:3–9.ArticlePubMedPMC
  • 27. Park J, Kim MH, Kim KP, et al. Natural history and prognostic factors of advanced cholangiocarcinoma without surgery, chemotherapy, or radiotherapy: a large-scale observational study. Gut Liver 2009;3:298–305.ArticlePubMedPMC
  • 28. Schutz SM, Abbott RM. Grading ERCPs by degree of difficulty: a new concept to produce more meaningful outcome data. Gastrointest Endosc 2000;51:535–539.ArticlePubMed
  • 29. Olsson G, Arnelo U, Swahn F, et al. The H.O.U.S.E. classification: a novel endoscopic retrograde cholangiopancreatography (ERCP) complexity grading scale. BMC Gastroenterol 2017;17:38.ArticlePubMedPMCPDF
  • 30. Ragunath K, Thomas LA, Cheung WY, et al. Objective evaluation of ERCP procedures: a simple grading scale for evaluating technical difficulty. Postgrad Med J 2003;79:467–470.ArticlePubMedPMCPDF
  • 31. Raju RP, Jaganmohan SR, Ross WA, et al. Optimum palliation of inoperable hilar cholangiocarcinoma: comparative assessment of the efficacy of plastic and self-expanding metal stents. Dig Dis Sci 2011;56:1557–1564.ArticlePubMedPDF
  • 32. Sangchan A, Chaiyakunapruk N, Supakankunti S, et al. Cost utility analysis of endoscopic biliary stent in unresectable hilar cholangiocarcinoma: decision analytic modeling approach. Hepatogastroenterology 2014;61:1175–1181.ArticlePubMed
  • 33. Sangchan A, Kongkasame W, Pugkhem A, et al. Efficacy of metal and plastic stents in unresectable complex hilar cholangiocarcinoma: a randomized controlled trial. Gastrointest Endosc 2012;76:93–99.ArticlePubMed
  • 34. Tierney J, Bhutiani N, Stamp B, et al. Predictive risk factors associated with cholangitis following ERCP. Surg Endosc 2018;32:799–804.ArticlePubMedPDF
  • 35. Everett BT, Naud S, Zubarik RS. Risk factors for the development of stent-associated cholangitis following endoscopic biliary stent placement. Dig Dis Sci 2019;64:2300–2307.ArticlePubMedPDF
  • 36. Yılmaz H, Koçyiğit B. Predictors of postendoscopic retrograde cholangiopancreatography associated cholangitis: a retrospective cohort study. Turk J Med Sci 2022;52:105–112.ArticlePubMedPMC
  • 37. Chen M, Wang L, Wang Y, et al. Risk factor analysis of post-ERCP cholangitis: a single-center experience. Hepatobiliary Pancreat Dis Int 2018;17:55–58.ArticlePubMed
  • 38. Khashab MA, Kim K, Hutfless S, et al. Predictors of early stent occlusion among plastic biliary stents. Dig Dis Sci 2012;57:2446–2450.ArticlePubMedPDF
  • 39. Naitoh I, Inoue T. Optimal endoscopic drainage strategy for unresectable malignant hilar biliary obstruction. Clin Endosc 2023;56:135–142.ArticlePubMedPMCPDF

Figure & Data

REFERENCES

    Citations

    Citations to this article as recorded by  

      • Cite
        CITE
        export Copy Download
        Close
        Download Citation
        Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

        Format:
        • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
        • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
        Include:
        • Citation for the content below
        Outcomes associated with bilateral plastic versus metal stents for palliation in malignant hilar biliary obstruction: an updated meta-analysis from the United States
        Clin Endosc. 2026;59(2):223-233.   Published online March 9, 2026
        Close
      • XML DownloadXML Download
      Figure
      • 0
      • 1
      • 2
      Related articles
      Outcomes associated with bilateral plastic versus metal stents for palliation in malignant hilar biliary obstruction: an updated meta-analysis from the United States
      Image Image Image
      Fig. 1. Literature review flowchart. Describes literature search methodology and exclusion criteria. MS, metal stent; PS, plastic stent.
      Fig. 2. Forest plots for (A) clinical success, (B) technical success, (C) adverse events, (D) post-procedural cholangitis, (E) recurrent biliary obstructiona), (F) endoscopic reintervention, and (G) percutaneous drainage. M-H, Mantel-Haenszel; CI, confidence interval; MS, metal stent; PS, plastic stent. a)Denotes statistical significance.
      Graphical abstract
      Outcomes associated with bilateral plastic versus metal stents for palliation in malignant hilar biliary obstruction: an updated meta-analysis from the United States
      Study Year Country Study size (n) Design PS (n) MS (n) Male (%) Age (yr, median or mean±SD) Follow-up endpoint Follow-up (day)
      PS MS PS MS PS MS PS MS
      Okuno et al.23 2023 Japan 76 Retrospective cohort 38 38 60 53 Median Median Death Death 871 1,116
      Paik et al.22 2024 Korea 50 Randomized controlled trial 25 25 60 56 70.4±9.7 71.6±9.8 Recurrent biliary obstruction Recurrent biliary obstruction 270 270
      Kim et al.24 2021 Korea 102 Retrospective cohort 67 35 60 69 Median Median Cholangitis, death Cholangitis, death 365 365
      Xia et al.25 2021 China 262 Retrospective cohort 96 96 60 54 64±12.2 65.8±13.0 Death Death 900 900
      Study Etiology of MHBO
      Okuno et al.23 Biliary tract cancer (54/76)
      Metastatic cancer, other site (17/76)
      Hepatocellular carcinoma (5/76)
      Paik et al.22 Cholangiocarcinoma (42/50)
      Gallbladder cancer (6/50)
      Metastatic cancer, other site (2/50)
      Kim et al.24 Cholangiocarcinoma (102/102)
      Xia et al.25 Cholangiocarcinoma (171/262)
      Gallbladder cancer (47/262)
      Hepatocellular carcinoma (27/262)
      Metastatic cancer, other site (17/262)
      Study PS MS
      Okuno et al.23 7 Fr, variable length Niti-S large cell D-type biliary stent, Bonastent M-hilar, HILZO stent, BileRush, Zilver 635 stent, Zeo stent, and JOSTENT SelfX stent, Hanarostent. All self-expanding MS were 8 mm or 10 mm in diameter. Placed either partially stent-in-stent or side by side.
      Paik et al.22 7 Fr straight (Cotton-Leung Biliary Stent) or double pigtail (Zimmon Biliary stent), variable length 10–15 cm Fully covered COMVI II stent. All self-expanding MS were 6 mm in diameter. Placed side by side.
      Kim et al.24 NR Uncovered self-expandable MS.
      Xia et al.25 7–10 F (Boston Scientific Matrik; Cook Medical) 12–18 cm in length Uncovered self-expandable MS. Boston Scientific or MicroTech. 6–8 mm in diameter and 8–12 cm in length.
      Study Study size (n) Design Technical success (n) Clinical success (n) Adverse event (n) Post-procedure cholangitis (n) Recurrence (n) Endoscopic reintervention (n) External (percutaneous) drainage (n)
      PS MS PS MS PS MS PS MS PS MS PS MS PS MS
      Okuno et al.23,a) 76 Retrospective cohort 38 37 37 37 2 6 20 19 20 19 20 19 0 3
      Paik et al.22 50 Randomized controlled trial 25 25 19 22 8 8 6 5 16 10 NR NR 1 1
      Kim et al.24 102 Retrospective cohort 67 35 44 25 NR NR NR NR NR NR 38 14 19 8
      Xia et al.25 192 Retrospective cohort 96 96 69 95 20 4 25 7 51 35 96 29 NR NR
      PS event (n) MS event (n) OR (95% CI) p-value
      Clinical success 169/226 179/194 0.32 (0.07–1.55) 0.16
      Technical success 226/226 193/194 3.08 (0.12–78.02) 0.50
      Adverse events 30/159 18/159 1.32 (0.25–7.09) 0.75
      Post-procedure cholangitis 51/159 31/160 1.96 (0.77–4.97) 0.16
      Recurrent obstruction 87/159 64/159 1.79 (1.15–2.81) 0.01a)
      Endoscopic reintervention 154/201 62/169 6.56 (0.52–82.08) 0.14
      Percutaneous drainage 20/130 12/98 1.01 (0.37–2.73) 0.98
      Table 1. Baseline characteristics of the included studies

      SD, standard deviation; PS, plastic stent; MS, metal stent.

      Table 2. Etiologies of MHBO by study

      MHBO, malignant hilar biliary obstruction.

      Table 3. Stent type and description

      PS, plastic stent; MS, metal stent; NR, not reported.

      Table 4. Data stratified by study and outcome

      PS, plastic stent; MS, metal stent; NR, not reported.

      Propensity score matching explains the discrepancy between n=76 with 38 PS and 37 MS.

      Table 5. Comparison of pooled event rates

      PS, plastic stent; MS, metal stent; OR, odds ratio; CI, confidence interval.

      Statistically significant difference. The p-value of difference percentages is also reported.


      Clin Endosc : Clinical Endoscopy Twitter Facebook
      Close layer
      TOP